Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.85 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 3:59 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONC) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/9/14 - C$1.80
52 Week Low
10/10/14 - C$0.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONC)

oncolytics biotech inc (ONC) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONC) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONC) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONC) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: C$530.0K
Chief Financial Officer
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: C$149.8K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONC) Key Developments

Oncolytics Biotech® Inc. Receives Extension To Regain Compliance From Nasdaq

Oncolytics Biotech® Inc. announced that it has received a letter from the NASDAQ OMX Group (Nasdaq) determining that the company is eligible for an additional 180-calendar day period, until October 26, 2015, to regain compliance with the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). Per the notice of deficiency received on October 29, 2014, Oncolytics had a period of 180-calendar days, or until April 27, 2015, to regain compliance with the minimum bid price requirement. Following a review, Nasdaq determined that the company was eligible to receive an additional 180-day period on the basis that Oncolytics still met the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and had provided written notice of its intention to cure the minimum bid price deficiency during the second 180-day compliance period by effecting a reverse stock split, if necessary. The company's shares continue to trade on the Toronto Stock Exchange (TSX) and are in full compliance with TSX listing requirements. The company's listing on the TSX is completely independent of, and will not be affected by, the status of its Nasdaq listing. If compliance cannot be demonstrated by October 26, 2015, Nasdaq staff will provide written notification that the company's securities will be delisted. At that time, the company may appeal Nasdaq staff's determination to a Hearings Panel.

Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas

Oncolytics Biotech Inc. announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of malignant glioma. The company applied for an ODD for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in patients of all ages. In three previous brain cancer studies including gliomas, REOLYSIN has been shown to infect a variety of brain tumors when delivered intravenously. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees. The receipt of Orphan Drug Designation status does not change the regulatory requirements or process for obtaining marketing approval.

Oncolytics Biotech Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 10:30 AM

Oncolytics Biotech Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 10:30 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONC:CN C$0.85 CAD 0.00

ONC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at